Sunho Biologics Inc

02898

Company Profile

  • Business description

    Sunho Biologics Inc is a clinical-stage biopharmaceutical company that focuses on the discovery, development and commercialization of biologics for the treatment of cancers and autoimmune diseases. It has three Core Products, IAH0968, IAP0971, and IAE0972, all of which are developed in-house. IAH0968 is an antibody-dependent cell-mediated cytotoxicity (ADCC) enhanced monoclonal antibody (mAb), and the company has initiated Phase II clinical trials for biliary tract carcinoma (BTC) and colorectal cancer (CRC). IAP0971 and IAE0972 are both immunocytokines and It has completed Phase I clinical trials for advanced solid tumors including non-small cell lung cancer (NSCLC) and CRC.

  • Contact

    No. 198 Peninsula Middle Road, Dipu Street
    Room 302, Building 3
    Anji County
    Zhejiang Province
    Huzhou
    CHN

    http://www.sunho-bio.com.cn

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    124

Stocks News & Analysis

stocks

2 undervalued ASX shares report

These two ASX shares are trading at a discount to our fair value. 
stocks

Turmoil at WiseTech

Board members step down over differences on the role of former CEO Richard White.
video

What does the RBA rate cut mean for investors?

Morningstar's Chief Investment Officer for Asia-Pacific and Director of Personal Finance share their thoughts on the recent RBA rate cut.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,498.0062.10-0.73%
CAC 408,090.9963.52-0.78%
DAX 4022,425.93138.370.62%
Dow JONES (US)43,461.2133.190.08%
FTSE 1008,658.980.39-0.00%
HKSE23,227.63113.98-0.49%
NASDAQ19,286.93237.08-1.21%
Nikkei 22538,281.45495.49-1.28%
NZX 50 Index12,307.27224.45-1.79%
S&P 5005,983.2529.88-0.50%
S&P/ASX 2008,251.9056.30-0.68%
SSE Composite Index3,367.255.77-0.17%

Market Movers